EZH2 and angioimmunoblastic T-cell lymphoma: We subsequently evaluated 16 patients with angioimmunoblastic T cell lymphoma (AITL) who received the CHOPE regimen at Peking University Cancer Hospital and found that individuals with elevated EZH2 expression exhibited reduced progression-free survival (PFS) (Supplementary Fig. S2G).